FORTE BIOSCIENCES INC

argenx is offering $77 per share in cash for Forte Biosciences, implying an equity value of about $2.2 billion and triggering a 39% rise in Forte’s stock. The agreement is a fully cash‑financed takeover offer with no financing condition; the boards of both companies have approved. The deal centers on the FB102 program, a first‑in‑class antibody targeting CD122 with positive Phase‑1b data in vitiligo and celiac disease; closing is expected in Q3 2026, subject to the tendering of shares and antitrust approval. » More on de.investing.com

The stock of Forte Biosciences rose to a 52-week high of $52.75 and is up 387.71% year-to-date in 2026, with a market capitalization of $1.27 billion and a beta of 2.84. InvestingPro rates the stock as overvalued relative to fair value and points to an overbought RSI. Barclays initiated coverage with “Overweight” and a $74.00 price target, citing positive phase‑1b results for FB102 in vitiligo that showed an average FVASI improvement of 29.6% at 24 weeks versus 7.9% for placebo and were already statistically significant by day 64. » More on de.investing.com

Alger Small Cap Focus Fund said Forte Biosciences detracted from Q2 performance after a poorly received equity raise and extended timelines for anticipated vitiligo data. The fund remains constructive on FB102, an anti‑CD122 monoclonal antibody with potential across celiac disease, vitiligo and alopecia areata, citing encouraging early celiac data. Forte closed at $47.49 on July 20 with a market cap near $972.5M and has delivered strong recent returns, while meaningful clinical readouts are expected later this year. The fund is cautiously optimistic on forthcoming results and sees strategic value if FB102’s clinical profile proves favorable. » More on finance.yahoo.com